Growth momentum JAMP Pharma Group has demonstrated steady turnover growth for over a decade and is expanding its manufacturing footprint in Quebec with recent facility acquisitions and new biosimilar launches, indicating continued capacity for higher-volume partnerships and contract manufacturing opportunities.

Biosk and generics The company is active in biosimilars and a large generics portfolio with near 345 molecules, plus recent biosimilar launches in Canada, presenting sales opportunities in close collaboration with hospitals, clinics, and provincial procurement programs seeking cost-effective biologic options.

Prostate cancer focus Recent introduction of Pr JAMP Enzalutamide strengthens a pivotal oncology niche; potential to cross-sell other oncology generics or biosimilars, as well as expansion into companion diagnostics, patient support programs, and retail/pharmacy channels.

Vertical expansion Strategic asset acquisitions and a new 100,000-square-foot production facility in Lévis signal readiness to scale manufacturing for domestic shortages; a sales opportunity for supply agreements, tender participation, and long-term contracts with Canadian health authorities.

Integrated capabilities Integrated departments (sales, R&D, regulatory, market access, logistics, QA) combined with a strong private-label and natural health products presence enable a holistic sales approach to distributors, clinics, and retailers seeking a diversified portfolio and end-to-end support.